Viking Therapeutics Inc. (VKTX) and Its Competitors Contrasting side by side.

As Biotechnology company, Viking Therapeutics Inc. (NASDAQ:VKTX) is competing with its rivals based on the institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Insider & Institutional Ownership

Viking Therapeutics Inc. has 61.8% of its shares owned by institutional investors & an average of 50.88% institutional ownership for its rivals. 8.7% of Viking Therapeutics Inc. shares are owned by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are owned by company insiders.


Table 1 has Viking Therapeutics Inc. and its competitors’ return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Viking Therapeutics Inc. 0.00% -15.80% -15.10%
Industry Average 1,464.25% 88.44% 21.62%

Earnings and Valuation

The following data compares Viking Therapeutics Inc. and its competitors’ net profit, top-line revenue and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Viking Therapeutics Inc. 20.91M N/A 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Ratings

Table 3 shows breakdown of recent ratings for Viking Therapeutics Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Viking Therapeutics Inc. 0 0 3 3.00
Industry Average 1.17 1.78 2.01 2.68

$29 is the average target price of Viking Therapeutics Inc., with a potential upside of 228.80%. As a group, Biotechnology companies have a potential upside of 173.20%. Given Viking Therapeutics Inc.’s competitors higher probable upside, equities research analysts plainly believe Viking Therapeutics Inc. has less favorable growth aspects than its competitors.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Viking Therapeutics Inc. and its competitors.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Viking Therapeutics Inc. -16.21% -32.62% -17.24% -10.92% 155.68% 133%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Viking Therapeutics Inc.’s stock price has bigger growth than the average for its competitors.


Viking Therapeutics Inc. has a Current Ratio of 64.6 and a Quick Ratio of 64.6. Competitively, Viking Therapeutics Inc.’s rivals Current Ratio is 7.68 and has 7.52 Quick Ratio. Viking Therapeutics Inc. has better ability to pay short and long-term obligations than Viking Therapeutics Inc.’s rivals.

Volatility and Risk

A beta of 2.89 shows that Viking Therapeutics Inc. is 189.00% more volatile than Standard and Poor’s 500. Competitively, Viking Therapeutics Inc.’s rivals are 70.08% more volatile than Standard and Poor’s 500, because of the 1.70 beta.


Viking Therapeutics Inc. does not pay a dividend.


On 3 of the 4 factors Viking Therapeutics Inc. beats Viking Therapeutics Inc.’s rivals.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder. In addition, it develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.